The Stress Kinase Mitogen-Activated Protein Kinase Kinase (Mkk)7 Is a Negative Regulator of Antigen Receptor and Growth Factor Receptor–Induced Proliferation in Hematopoietic Cells by Sasaki, Takehiko et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/09/757/12 $5.00
Volume 194, Number 6, September 17, 2001 757–768
http://www.jem.org/cgi/content/full/194/6/757
 
757
 
The Stress Kinase Mitogen-activated Protein Kinase Kinase 
(MKK)7 Is a Negative Regulator of Antigen Receptor and 
Growth Factor Receptor–induced Proliferation in 
Hematopoietic Cells
 
Takehiko Sasaki,
 
1, 2 
 
Teiji Wada,
 
1, 2 
 
Hiroyuki Kishimoto,
 
3
 
Junko Irie-Sasaki,
 
1, 2 
 
Goichi Matsumoto,
 
1, 2 
 
Takayuki Goto,
 
3
 
Zhengbin Yao,
 
4
 
 Andrew Wakeham,
 
1, 2 
 
Tak W. Mak,
 
1, 2 
 
Akira Suzuki,
 
1, 2
 
Sarah K. Cho,
 
2
 
 Juan Carlos Zuniga-Pﬂucker,
 
2
 
Antonio J. Oliveira-dos-Santos,
 
1, 2 
 
Toshiaki Katada,
 
3
 
 Hiroshi Nishina,
 
3
 
 
 
and Josef M. Penninger
 
1, 2
 
1
 
Amgen Institute, Ontario Cancer Institute, and the 
 
2
 
Departments of Medical Biophysics and 
Immunology, University of Toronto, Toronto, Ontario, Canada M5G 2C1
 
3
 
Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku,
Tokyo 113-003, Japan
 
4
 
Department of Pathology, Amgen Incorporated, Thousand Oaks, CA 91320
 
Abstract
 
The dual specificity kinases mitogen-activated protein kinase (MAPK) kinase (MKK)7 and
MKK4 are the only molecules known to directly activate the stress kinases stress-activated
protein kinases (SAPKs)/c-Jun N-terminal kinases (JNKs) in response to environmental or
mitogenic stimuli. To examine the physiological role of MKK7 in hematopoietic cells, we
used a gene targeting strategy to mutate MKK7 in murine T and B cells and non-lymphoid
mast cells. Loss of MKK7 in thymocytes and mature B cells results in hyperproliferation in re-
sponse to growth factor and antigen receptor stimulation and increased thymic cellularity.
Mutation of 
 
mkk7 
 
in mast cells resulted in hyperproliferation in response to the cytokines in-
terleukin (IL)-3 and stem cell factor (SCF). SAPK/JNK activation was completely abolished
in the absence of MKK7, even though expression of MKK4 was strongly upregulated in
 
mkk7
 
 
 
/
 
 
 
 mast cell lines, and phosphorylation of MKK4 occurred normally in response to
multiple stress stimuli. Loss of MKK7 did not affect activation of extracellular signal–regulated
kinase (ERK)1/2 or p38 MAPK. 
 
mkk7
 
 
 
/
 
 
 
 mast cells display reduced expression of JunB and
the cell cycle inhibitor p16INK4a and upregulation of cyclinD1. Reexpression of p16INK4a
in 
 
mkk7
 
 
 
/
 
 
 
 mast cells abrogates the hyperproliferative response. Apoptotic responses to a vari-
ety of stimuli were not affected. Thus, MKK7 is an essential and specific regulator of stress-
induced SAPK/JNK activation in mast cells and MKK7 negatively regulates growth factor
and antigen receptor–driven proliferation in hematopoietic cells. These results indicate that
the MKK7-regulated stress signaling pathway can function as negative regulator of cell growth
in multiple hematopoietic lineages.
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grams and environmental agents trigger distinct and evolu-
tionarily conserved signal transduction cascades that relay
signals mediating proliferation, survival, or death. The mi-
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Introduction
 
During the development of all multicellular organisms, cell
fate decisions determine whether cells undergo prolifera-
tion and differentiation, or apoptosis. Developmental pro- 
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togen-activated protein kinases (MAPKs)
 
*
 
 are a family of
serine/threonine kinases which transduce signals from the
cell membrane to the nucleus in response to a wide range
of stimuli (1, 2). These molecules participate in several dif-
ferent intracellular signaling pathways that control a spec-
trum of cellular processes, including cell growth, differenti-
ation, transformation, apoptosis, and stress responses (3, 4).
Important members of the MAPK family are the extracel-
lular signal-regulated kinases ERK1 and ERK2, ERK5,
p38 MAPK, and the stress-activated protein kinases
(SAPKs, also known as the c-Jun N-terminal kinases
[JNKs]) (5, 6).
SAPKs/JNKs are activated in response to a variety of
cellular stresses such as changes in osmolarity or metabo-
lism, DNA damage, heat shock, ischemia, shear stress, in-
flammatory cytokines such as TNF and IL-1, and ceramide
(3, 4, 7). Once activated, SAPKs/JNKs regulate gene tran-
scription via phosphorylation of transcription factors, in-
cluding c-Jun, JunD, activating transcription factor (ATF)-2,
nuclear factor of activated T cells (NFAT)4, or ELK-1 (8).
Biochemical analyses have indicated that SAPK/JNKs and
SAPK/JNK-regulated signaling pathways are involved in
cell fate decisions resulting in apoptosis, oncogenic trans-
formation, activation of T and B lymphocytes, induction of
proinflammatory cytokines, regulation of proliferation and
cell cycle arrest, and cardiovascular, renal, and hepatic stress
responses (3, 4). Genetic analyses have confirmed that
SAPKs/JNKs regulate T cell activation (9), Th1/Th2 dif-
ferentiation (10), neuronal cell death (11), UV-induced cell
death in fibroblasts (12), and dorsal closure during 
 
Dro-
sophila
 
 development (13).
The prototypical MAPK phosphorylation cascade con-
sists of a MAPK kinase kinase (MAPKKK or MEKK), a
MAPK kinase (MKK), and a MAPK (14, 15). MAPKKK
phosphorylate and activate MKK, dual-specificity protein
kinases that in turn phosphorylate MAPK. Activation of
MAPKs requires phosphorylation of both the threonine
and tyrosine residues in the Thr-X-Tyr motif. Several
mammalian MKKs have been identified to date, including
MEK1, MEK2, MKK3, MKK4 (also known as SEK1 or
JNKK1), MEK5, MKK6 (16–18), and MKK7 (SEK2,
JNKK2; references 19–22). SAPKs/JNKs are activated di-
rectly by MKK4 and MKK7, but by no other MKKs. Re-
cent studies of murine embryonic stem (ES) cells lacking
the 
 
mkk4
 
 gene (23–25) have demonstrated that MKK4 is
critical for the activation of SAPKs/JNKs in response to the
protein synthesis inhibitor anisomycin or heat shock. How-
ever, SAPK/JNK activity was still inducible in 
 
mkk4
 
-defi-
cient ES cells subjected to UV-irradiation or changes in os-
molarity. Loss of MKK7 in ES cells abrogates, but does not
abolish, SAPK/JNK activation in response to osmolarity
 
changes, UV-irradiation, heat shock, or anisomycin (10).
In addition, D-MKK4 and D-MKK7 serve nonredundant
functions in 
 
Drosophila
 
 (3). These results implied that the
SAPK/JNK activators MKK7 and MKK4 operate indepen-
dently and that different stresses utilize distinct MAPK sig-
naling pathways to activate SAPKs/JNKs.
Recently is has been shown that 
 
mkk7
 
-deficient and
 
jnk1/jnk2
 
 double mutant T cells hyperproliferate in re-
sponse to antigen receptor crosslinking (10), suggesting that
the MKK7-regulated stress kinase signaling pathway might
negatively regulate T cell activation. Whether genetic inac-
tivation of MKK7 expression has also a role in the activa-
tion and proliferation of other hematopoietic cells is not
known. We generated 
 
mkk7
 
 
 
/
 
 
 
 chimeric mice using re-
combination activating gene (
 
rag
 
)
 
1
 
 blastocyst complemen-
tation and a gene targeting strategy that allowed us to ana-
lyze the function of MKK7 in T and B lymphocytes and
non-lymphoid bone marrow mast cell lines (BMMCs).
 
mkk7
 
 
 
/
 
 
 
rag1
 
 
 
/
 
 
 
 chimeric mice have enlarged thymi, and
thymocytes from these mice hyperproliferate in response to
antigen receptor stimulation. Similarly, 
 
mkk7
 
 deficiency
leads to hyperproliferation of B cells and BMMCs after
stimulation of antigen or growth factor receptors. Mutation
of 
 
mkk7 
 
in BMMCs results in loss of expression of JunB
and the cell cycle inhibitor p16INK4a and upregulation of
cyclinD1. In BMMCs, MKK7 is required to relay signaling
in response to IgE, anisomycin, UV-irradiation, or NaCl
stimulation to activation of SAPKs/JNKs. Ectopic reex-
pression of p16INK4a in 
 
mkk7
 
 
 
/
 
 
 
 mast cells abrogates the
hyperproliferative response. This study shows that a stress
signaling kinase, i.e., MKK7, can negatively regulate the
proliferation of multiple hematopoietic cell lineages.
 
Materials and Methods
 
mkk7 Gene Targeting and Construction of Somatic Chimeras.
 
A
12-kb genomic 
 
mkk7
 
 fragment was isolated from a 129/Ola
mouse library and inserted into the NotI site of pBluescript II. A
targeting vector was constructed containing a 709-bp short arm
and a 5.4-kb long arm of homology flanking a neomycin resis-
tance cassette (Neo) inserted into the EcoRI/Bgl-II sites of the
genomic clone in antisense orientation to 
 
mkk7
 
 transcription.
The linearized construct was electroporated into 10
 
7
 
 E14K ES
cells derived from 129/Ola mice. ES cell colonies resistant to
G418 [0.3 mg/ml] were screened for homologous recombina-
tion by PCR using primers specific for 
 
mkk7
 
 genomic sequences
and Neo. Recombinant colonies were confirmed by Southern
blotting of XbaI-digested genomic DNA hybridized to a 530-bp
3
 
 
 
 flanking probe. E14K ES cells heterozygous for the 
 
mkk7
 
 mu-
tation were retargeted using a hygromycin-resistance cassette that
replaced parts of exon 13 and exon 14 of the 
 
mkk7
 
 gene. For
construction of somatic chimeras, two independent 
 
mkk7
 
 
 
/
 
 
 
 ES
cell clones (
 
mkk7
 
neo/hyg
 
) and a 
 
mkk7
 
 
 
/
 
 
 
 (
 
mkk7
 
 
 
/neo
 
) E14K ES cell
clone were injected into 3.5 day 
 
rag1
 
 
 
/
 
 
 
 blastocysts and trans-
ferred to pseudopregnant foster mothers as described (26). As
E14 ES cells are derived from 129/Ola mice, age-matched 129/
Ola mice were used as wild-type controls in some experiments.
For Northern blotting, total RNA (20 
 
 
 
g) was isolated from
lymph node cells, thymocytes, spleen cells, and mast cell lines,
electrophoresed, transferred to a Hybond-N membrane (Amer-
 
*
 
Abbreviations used in this paper: 
 
7-AAD, 
 
7
 
-amino-actinomycin D;
BMMC, bone marrow mast cell; DN, double negative; DP, double posi-
tive; ERK, extracellular signal–regulated kinase; ES, embryonic stem;
JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase;
MKK, MAPK kinase; 
 
rag
 
, recombination activating gene; SAPK, stress-
activated protein kinase; SCF, stem cell factor; SP, single positive. 
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sham Pharmacia Biotech), and hybridized with probes specific
for 
 
mkk7 
 
(22). All data presented in this study were obtained
from two independently derived 
 
mkk7
 
 
 
/
 
 
 
 ES cell clones, and all
results were comparable between them. If not otherwise stated,
all mice used for experiments were between 6–10 wk of age. All
mice were maintained at the animal facilities of the Ontario Can-
cer Institute under specific pathogen-free conditions according to
institutional guidelines.
 
Immunocytometry.
 
Single cell suspensions of thymi, lymph
nodes, bone marrow, blood, and spleens from 
 
mkk7
 
 
 
/
 
 
 
, 
 
mkk7
 
 
 
/
 
 
 
rag1
 
 
 
/
 
 
 
, and 
 
mkk7
 
 
 
/
 
 
 
rag1
 
 
 
/
 
 
 
 chimeras were stained with FITC-,
PE-, or biotin-conjugated Abs reactive to: Thy1.2, CD3
 
 
 
,
TCR
 
 
 
/
 
 
 
, TCRV
 
 
 
6, TCRV
 
 
 
8.1/8.2, TCRV
 
 
 
14, TCR
 
 
 
/
 
 
 
,
CD4, CD8, CD25, CTLA4, CD28, CD95 (FAS), CD5, CD44,
CD45, CD69, CD11a (LFA-1), CD11b (Mac-1), MHC class II
(I-Ab), CD23, B220, CD43, sIgM, sIgD, CD19, or Gr-1 (all
Abs were from BD PharMingen). For the analysis of thymocyte
precursors, single cell suspensions were stained with PE-conju-
gated anti-CD4, anti-CD8, anti-CD3
 
 
 
, anti-B220, anti-CD11b,
anti-Gr-1, and anti-TCR
 
 
 
/
 
 
 
; FITC-conjugated anti-CD25;
and biotin-conjugated anti-CD44. PE-negative precursor cells
(triple-negative thymocytes) were analyzed for expression of
CD25 and CD44. Biotinylated Abs were visualized using
streptavidin-RED670 (GIBCO BRL). All samples were ana-
lyzed by flow cytometry using a FACScan™ (Becton Dick-
inson).
 
Lymphocyte Proliferation, Cytokine Production, and Thymocyte Ap-
optosis.
 
For proliferation assays, purified lymph node T cells
(10
 
5
 
 cells/well) were placed into round bottom 96-well plates
(Nunc) in freshly prepared IMDM (10% FCS, 10 
 
 
 
M 
 
 
 
-mer-
captoethanol) and stimulated with PMA plus the Ca
 
2
 
 
 
 iono-
phore A23617, soluble anti-CD3
 
 
 
 (clone 145-2C11, hamster
IgG), soluble anti-CD28 (clone 37.51; BD PharMingen), or the
mitogen Con A (Amersham Pharmacia Biotech). B cells (10
 
5
 
cells/well) were stimulated with anti-IgM (61-6800; Zymed
Laboratories), anti-IgM F(ab
 
 
 
)
 
2
 
 fragment (61-5900; Zymed Lab-
oratories), anti-CD40 (clone 145-2C11; BD PharMingen), or
LPS (Sigma-Aldrich). Cells were stimulated in triplicate for dif-
ferent time periods and pulsed for the last 12 h with 1 
 
 
 
Ci/well
[
 
3
 
H]thymidine (Amersham Pharmacia Biotech). [
 
3
 
H]Thymidine
incorporation was measured using a 
 
 
 
-scintillation counter
(Coulter). To determine cytokine production in these cultures,
the culture supernatants were removed and assayed in triplicate
for the production of IL-2 and IFN-
 
 
 
 using ELISA (R&D Sys-
tems).
 
 
 
For the analysis of thymocyte apoptosis, single cell suspen-
sions were cultured for various times in 24-well flat bottom tis-
sue culture plates (Nunc) at a density of 2 
 
 
 
 10
 
6
 
/ml in IMDM
(10% FCS, 10 
 
 
 
M 
 
 
 
-mercaptoethanol). The following stimuli
were administered: anisomycin (10 
 
 
 
g/ml; Sigma-Aldrich);
LY294002 (50  M; Sigma-Aldrich); dexamethasone (10 nM;
Sigma-Aldrich); anti-CD95 (FAS) (Jo2; BD PharMingen); sorbi-
tol (0.4 M; Sigma-Aldrich); NaCl (0.3 M); heat shock (43 C, 30
min); or anti-CD3  (clone 145-2C11, hamster IgG; BD Phar-
Mingen). In the latter case, anti-CD3  was immobilized on the
plates with 10  g/ml rabbit anti–hamster IgG (Jackson Immu-
noResearch Laboratories). At various time points after stimula-
tion, thymocytes were harvested, stained with the vital dye
7-amino-actinomycin D (7-AAD), anti-CD4, and anti-CD8,
and subjected to flow cytometric analysis. Apoptosis was con-
firmed using Annexin V staining to visualize membrane changes,
propidium iodide (PI) staining and trypan blue exclusion to test
for membrane integrity, and DIOC6[3] staining to test for mito-
chondrial potential.
BMMC Lines. Bone marrow cells were flushed from femurs
of  mkk7 / rag1 /  chimeric and control mice. Cells were
washed twice with PBS and resuspended at 5   105/ml in Opti-
MEM medium supplemented with 10% FCS, 50  M  -mercap-
toethanol, antibiotics (penicillin plus streptomycin; GIBCO/
BRL), and 2 ng/ml IL3 (Genzyme). BMMCs were isolated by
continuous transfer of cells growing in suspension as described
(27). Proliferation of BMMCs was assessed by [3H]thymidine in-
corporation. In brief, cells were deprived of IL-3 for 12 h, cul-
tured in the presence of various concentrations of IL-3 or stem
cell factor (SCF) for 24 h, and pulse-labeled with [3H]thymidine
for 12 h. For cell death assays, BMMCs were deprived of IL-3
and/or serum, or stimulated with NaCl, UV-irradiation, aniso-
mycin, or heat shock as above. At various time points after stimu-
lation, apoptosis was determined in triplicate cultures by 7-AAD
and Annexin V staining. Cell cycle progression was monitored
using PI staining. For infection experiments, pBabe-puro or
pBabe-puro–expressing p16INK4a (gift of E. Wagner, Institute
for Molecular Pathology, Vienna, Austria) were transfected into a
phoenix-E packaging cell line. mkk7 /  BMMCs were cultured
in the culture supernatant of the packaging cells for 1 d and se-
lected with 2.5  g/ml puromycin for 1 wk. In vitro generation
of B220 IgM  B cells and Fc R c-Kit  mast cells from mkk7-
mutant ES cell lines was as described (28, 29).
Signal Transduction. BMMCs (2   106/100  l) were cultured
in medium alone or stimulated with IL-3 (30 ng/ml), NaCl (0.5
M), anisomycin (10  g/ml), UV-irradiation (500 mJ, using a
DNA-Stratalinker; Stratagene), heat shock (45 C in a prewarmed
waterbath), cycloheximide (50  g/ml), or TNF  (100 ng/ml),
for various time periods. For Fc R stimulation, cells were incu-
bated with anti-DNP IgE mAb (7  g/ml, clone SPE7; Sigma-
Aldrich) for 1 h on ice, followed by the addition of 50 ng/ml
DNP (Sigma-Aldrich) at 37 C to crosslink the Fc R. Cells were
pelleted by centrifugation and resuspended in 100  l ice cold lysis
buffer (1% Triton X-100, 10 mM Tris/HCl, pH 7.4, 150 mM
NaCl, 30 mM Na4P2O7, 5 mM EDTA, 50 mM NaF, 1 mM phe-
nylmethylsulfonyl fluoride, and 1 mM Na3VO4). Cell lysates
were fractionated by SDS-PAGE and the proteins transferred
to PVDF membranes and immunoblotted. Activation of p38
MAPK, ERK1/2, and PKB/Akt was detected using Abs specific
for phospho-p38 MAPK (Thr180/Tyr182), phospho-ERK1/2
(Thr202/Tyr204), phospho-PKB/Akt (Ser473 and Thr308), or
phospho-MKK4 (Thr223; New England Biolabs, Inc. or Upstate
Biotechnology), because phosphorylation at these sites has been
shown to induce activation of these kinases. To verify equivalent
loading and to confirm the identity of the phosphorylated pro-
teins, membranes were stripped and blotted with Abs to non-
phosphorylated PKB/Akt, ERK1/ERK2, SAPKs/JNKs, p38
MAPK (all from Santa Cruz Biotechnology, Inc.), and MKK4
(Upstate Biotechnology) or actin (Sigma-Aldrich). Protein levels
of p16INK4a, p27, actin, JunB, cyclinD1 (Santa Cruz Biotech-
nology, Inc.), and MKK7 (BD Transduction) were determined in
total cell lysates by immunoblotting followed by visualization
using enhanced chemoluminescence (ECL). For detection of
SAPK/JNK kinase activity, total SAPKs/JNKs were immunopre-
cipitated (1 h, 4 C) from BMMC lysates using polyclonal rabbit
anti-SAPK/JNK IgG reactive against all SAPK/JNK isoforms (5).
Immune complexes were harvested on protein A-Sepharose
beads. For kinase assays, immune complexes were washed three
times with the lysis buffer. The beads were resuspended in 20  l
kinase buffer (10 mM MgCl2, 50 mM Tris-Cl, pH 7.5, 1 mM
EGTA, pH 7.5) and SAPK/JNK activity was assayed at 30 C for
30 min in the presence of 1  Ci [ -32P]ATP using 5  g GST-760 Hematopoietic Cells Lacking MKK7 Hyperproliferate
c-Jun as the in vitro substrate. The reaction was stopped by the
addition of 5  SDS sample buffer. GST-c-Jun phosphorylation
was visualized by autoradiography as described previously (5).
Results
Targeted Disruption of the Mouse mkk7 Gene. To disrupt
the murine mkk7 gene in E14K ES cells, a portion of exon
9, including the phosphorylation motif, was replaced with a
PGK-Neo cassette (Fig. 1 A). Because homozygous inacti-
vation of the mkk7 gene in mice leads to embryonic lethal-
ity (reference 10, and our own unpublished data), we tar-
geted the second allele in mkk7 /  PGK-Neo ES cells
using a different targeting vector containing a hygromycin
resistance cassette (Hygro; Fig. 1 B). This vector targeted a
different region (parts of exons 13 and 14) of the mkk7
gene, allowing us to ascertain homologous recombination
at both alleles (Fig. 1 C). Disruption of both mkk7 alleles in
ES cells was confirmed by Southern blot analysis of ge-
nomic DNA (Fig. 1 D) and Western blotting (Fig. 1 F).
To study the development and activation of T and B cells
in the absence of MKK7, two different mkk7 /  (mkk7Neo/Hyg)
ES cell lines were used to generate mkk7 / rag1 /  chi-
meric mice via rag1 blastocyst complementation (23). The
capacity for hygromycin selection also permitted us to gen-
erate mkk7 /  BMMCs from the chimeric mice. Loss of
mkk7 mRNA expression in several different cell types from
mkk7 / rag1 /  mice was confirmed by Northern blot
analysis. No detectable mkk7 mRNA expression could be
found in RNA isolated from mutant ES cells (not shown),
thymocytes, lymph nodes, or two different BMMC lines
(Fig. 1 E). Absence of mkk7 mRNA expression was con-
firmed by reverse transcription (RT)-PCR (not shown).
Thus, our gene targeting strategy provided us with a means
of analyzing the role of MKK7 in multiple hematopoietic
cell lineages, i.e., T and B lymphocytes and BMMCs.
Increased Thymocyte Proliferation and Thymic Cellularity in
mkk7 / rag1 /  Mice. Although mkk7 / rag1 /  chi-
meric mice showed normal numbers and subpopulations of
peripheral T cells, we were surprised to observe that these
animals displayed thymi of significantly increased cellularity
(Table I). The proportions of CD4 CD8  double negative
(DN) progenitor cells, immature CD4 CD8  double posi-
tive (DP) cells, and mature CD4  and CD8  single positive
(SP) thymocytes were equal in mkk7 / rag1 /  and mkk7 / 
rag1 /  thymi (Fig. 2 A). Moreover, there were no differ-
ences in surface expression levels of TCR / , CD3, CD4,
CD8, CD28, CD45, TCRV  subclasses, or CD95 on SP
or DP thymocytes (not shown). The maturation of DN
precursor populations as defined by c-Kit, CD44, and
CD25 surface expression, and the maturation of immature
DP thymocytes to mature SP thymocytes as defined by
CD69, CD44, HSA, CD5, and H2-Kb expression, were
also similar in mkk7 / rag1 /  and mkk7 / rag1 /  thy-
mocyte populations. Thus, MKK7 is not required for thy-
mocyte development or thymic positive selection. How-
ever, loss of MKK7 leads to increased thymic cellularity.
Thymic cellularity is maintained by a balance between
apoptosis and cellular proliferation, activities that in many
cell types involve SAPK/JNK signaling. To examine the
impact of MKK7 deficiency on thymocyte survival, we
evaluated the responses in vitro of mkk7 / rag1 /  thy-
mocytes to treatment with anti-CD3  or anti-FAS (CD95),
stimuli known to induce the apoptotic death of DP thy-
mocytes. No apparent differences in the kinetics or extents
of cell death were observed between mutant and control
thymocytes after stimulation of either CD3  (Fig. 2 B) or
FAS (Fig. 2 C). Furthermore, the susceptibility of mkk7 / 
thymocytes to apoptosis induced by anisomycin, the PI3K
inhibitor LY294002, sorbitol (osmotic shock), or dexa-
methasone was comparable to that of mkk7 /  chimeric thy-
Figure 1. Gene targeting of mkk7. (A–C) Partial restriction map of ge-
nomic mkk7 sequences and construction of the neomycin resistance (Neo)
(A) and hygromycin resistance (Hyg) (B) insertion vectors. The 14 exons
of murine mkk7 are shown as filled boxes. The genomic mkk7 flanking
probe used for Southern blotting is indicated in C. Restriction enzymes
used for construction of the vectors and genomic Southern blotting (XbaI)
are indicated. B, BamHI; H, HindIII; E, EcoRI. (D) Genomic analysis of
ES cells. Genomic DNA was isolated from wild-type mkk7 /  ( / ),
mkk7 /neo (  / ), and mkk7neo/hyg (  / ) E14 ES cells, digested with
XbaI, and analyzed by Southern blotting using the 3  flanking probe indi-
cated in C. Molecular weight markers and the wild-type (wt) and two
mutant bands are indicated. (E) Northern blot analysis of mkk7 mRNA
expression in thymocytes (Thy), lymph nodes, and BMMCs isolated from
wild-type ( / ) and mkk7 / rag1 /  ( / ) chimeric mice. Total RNA
(20  g) was probed using full-length mkk7 or  -actin cDNA. (F) Western
blot analysis of MKK7 expression in ES cells.761 Sasaki et al.
mocytes (Fig. 2 D). However, mkk7-deficient thymocytes
exhibited hyperproliferation in response to antigen recep-
tor engagement (Fig. 2 E). These data imply that antigen
receptor–triggered hyperproliferation of thymocytes, and
not reduced cell death, accounts for the increased thymic
cellularity in mkk7 / rag1 /  chimeric mice. However, as
mainly single positive thymocyte proliferate in our assays,
we cannot exclude the possibility that MKK7 controls thy-
mocyte cell death in response to a yet unidentified signals
that controls cellularity. Moreover, MKK7 could control
proliferation of DN progenitor cells.
Activation of mkk7-deficient Peripheral T Cells. The
SAPK/JNK signaling pathway has been shown to integrate
antigen receptor and costimulatory signals in primary T
cells and T cell lines (30) and to control Th1/Th2 differen-
tiation (10, 31). It has also been reported that T cells bear-
ing mutations of either mkk4 or jnk2 display partial defects
in cell proliferation and IL-2 production in response to
suboptimal stimulation of the TCR plus CD28 (9, 32). In
addition, transfection and pharmacological inhibitor studies
have suggested that MKK7 might regulate production of
IL-2 in T cell lines (33). On the other, it has been reported
in  mkk7 and jnk1/jnk2 double mutant T cells that the
MKK7-SAPK/JNK signaling pathway has no role in T cell
activation but rather influences effector functions (10).
Moreover, the same group reported that mkk7 and jnk1/
jnk2 double mutant T cells hyperproliferate and produce
more IL-2 in in vitro stimulation assays (10). We therefore
explored whether the absence of MKK7 had a similar effect
on the numbers, activation, or function of peripheral T
cells in our chimeric mice. Lymph nodes and spleens of
Table I. Lymphocyte Populations in mkk7 /  Chimeric Mice
Subsets
mkk7 / 
→rag1 / 
mkk7 / 
→rag1 / 
Thymus
Total cell number ( 107) 9.84   2.2 22.5   4.6
CD4 CD8  (%) 81.2   7.6 88.9   2.3
CD4 CD8  (%) 11.8   5.0 7.60   1.2
CD4 CD8  (%) 2.5   0.8 1.2   0.4
Spleen
Total cell number ( 107) 2.90   0.6 2.74   0.4
TCR /   (%) 36.3   4.3 33.8   4.9
B220 sIgM  (%) 29.9   5.4 27.8   5.6
Lymph node
Total cell number ( 107) 2.96   0.4 3.14   0.3
CD4 CD8  (%) 53.2   4.0 43.6   2.6
CD4 CD8  (%) 19.7   1.6 15.5   2.8
7–12-wk-old  mkk7 / →rag1 /  and mkk7 / →rag1 /  mice were
used. Total cells from thymi (n   8), spleen (n   5), and lymph nodes
(n    5) were stained with Abs against the indicated proteins and
populations determined by FACScan™. Bold numbers indicate
statistically significant differences between mkk7 /  and mkk7 / 
chimeric mice (Student’s t test; P   0.05). Values are given as the
mean   S.E.M.
Figure 2. Loss of MKK7 expression results in increased thymic cellu-
larity and thymocyte hyperproliferation. (A) Immunocytometric analysis
of thymocytes in mkk7 /  and mkk7 /  chimeric mice. Cells were iso-
lated from 6-wk-old mice and stained with anti-CD4 and anti-CD8. Per-
centages of positive cells within a quadrant are indicated. One result rep-
resentative of eight independent experiments is shown. (B–D) Induction
of cell death in thymocytes from mkk7 /  and mkk7 /  chimeric mice.
Freshly isolated thymocytes were stimulated for 20 h with (B) the indi-
cated concentrations of anti-CD3 ; (C) anti-CD95 (anti-FAS); and (D)
anisomycin (Ani; 10  g/ml), the PI3K inhibitor LY294002 (LY; 50  M),
sorbitol (Sor; 0.4 M), or dexamethasone (Dex; 10 nM). Thymocytes were
stained with anti-CD4–PE, anti-CD8–FITC, and the vital dye 7-AAD,
and viable CD4 CD8  cells (7-AAD–negative) were determined by
FACS® in triplicate. Values represent mean percentages of viable
CD4 CD8  DP thymocytes and are normalized to the percentage of via-
ble DP cells in untreated cultures (100%). Spontaneous apoptosis was
comparable between mkk7 /  and mkk7 /  thymocytes both at the start
of culture and after 20 h (not shown). One result representative of eight
independent experiments is shown for each activation. (E) Thymocyte
proliferation. Thymocytes (105/well) were isolated from mkk7 /  and
mkk7 /  chimeric mice and activated with the indicated concentrations
of plate-bound anti-CD3  mAbs. Proliferation was determined in tripli-
cate (  SD) at 48 h after a 12-h pulse with [3H]thymidine. One result
representative of five independent experiments is shown.762 Hematopoietic Cells Lacking MKK7 Hyperproliferate
mkk7 / rag1 /  chimeric mice contained normal numbers
and ratios of CD4  and CD8  T cells (Table I and Fig. 3
A). Moreover, the surface levels of TCR / , CD3, CD4,
CD8, CD28, CD45, CD44, LFA1, CD25, and CD69 on
both splenic and lymph node CD4  and CD8  T cells
were comparable in mkk7 / rag1 /  and mkk7 / rag1 / 
mice (not shown). Thus, despite enhanced thymic cellular-
ity, loss of MKK7 does not affect cell numbers or surface
phenotypes of peripheral T cells.
To investigate the role of MKK7 in T cell function, we
analyzed the activation and proliferation of peripheral T
cells in response to different concentrations of anti-CD3 
Ab, anti-CD3  plus anti-CD28 Abs, the mitogen Con A,
or PMA/calcium-ionophore, stimuli that bypass the initial
antigen receptor signal. At all doses and stimuli tested, the
kinetics (not shown) and extents (Fig. 3 B) of proliferation
were comparable between mkk7 / rag1 /  and mkk7 / 
rag1 /  lymph node T cells. Similarly, IL-2 and IFN-  pro-
duction by lymph node T cells was also normal in the ab-
sence of MKK7 (not shown). It should be noted that in
some experiments we observed increased proliferation as
well as increased IL-2 and IFN-  production by mkk7 / 
T cells compared with mkk7 /  T cells; however, this
increased proliferation was never statistically significant.
These results show that loss of MKK7 has no apparent effect
on peripheral T cell homeostasis, activation or function.
MKK7 Is a Negative Regulator of B Cell Proliferation.
SAPK/JNK activation has been implicated in signal trans-
duction downstream of B cell stimulation via CD40 en-
gagement or LPS treatment (34). However, no proliferative
or functional defects were apparent in B cells from mice de-
ficient for mkk4, jnk1, or jnk2 (31, 35, 36). mkk7 / rag1 / 
chimeric mice displayed normal numbers and differen-
tiation of B220 CD25 , B220 CD25 , B220 CD43 ,
B220 CD43 , B220 sIgM , and CD19 sIgM sIgD  B
cells in the bone marrow, and normal populations of
B220 sIgM sIgD  B cells in peripheral lymphoid organs
(Table I, Fig. 4 A, and not shown). Basal serum levels of the
Ig subclasses IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA were
also comparable in mkk7 / rag1 /  and mkk / rag1 /  chi-
meric mice (not shown). Thus, B cell development in the
bone marrow and mature B cell populations in the periph-
ery appear normal in the absence of MKK7.
To determine whether MKK7 is required for B cell acti-
vation, we measured B cell proliferation in response to LPS
treatment, anti-CD40 Ab, IgM (Fab )2 crosslinking, and
the engagement of IgM plus CD40. Intriguingly, the pro-
liferation of mkk7 / rag1 /  B cells was significantly en-
hanced in response to anti-IgM (Fab )2 crosslinking (Fig. 4
B). The increased proliferative response was still observed
when mkk7-deficient cells were stimulated with the intact
anti-IgM Ab, suggesting that the hyperproliferation is not
due to impaired negative signals mediated via Fc RIIB
(not shown). The proliferation of mkk7-deficient B cells
was also markedly enhanced by treatment with LPS, anti-
CD40, or anti-IgM (Fab )2 plus anti-CD40 (Fig. 4 B).
Thus, as was true for thymocytes, loss of MMK7 in B cells
results in hyperproliferation in response to growth stimuli
or engagement of the antigen receptor.
MKK7 Negatively Regulates Growth Factor–dependent Pro-
liferation of Mast Cells. SAPKs/JNKs and their activators
MKK4 and MKK7 are expressed in all hematopoietic lin-
eages. However, the role of MKK7 and SAPKs/JNKs in
the function of non-lymphoid hematopoietic cells has not
been explored using mutational analysis. Our targeting
strategy of mutating one mkk7 allele with a Neo-cassette
and the other allele with a hygromycin-resistance vector al-
lowed us to study the role of MKK7 in a non-lymphoid
hematopoietic lineage, BMMC lines. Because mast cells
derived from mkk7 /  ES cells in the chimeric mice (but
not those derived from rag1 /  ES cells) were resistant to
hygromycin, several BMMC lines known to be mkk7 / 
could readily be established (Fig. 1 E). As controls, we gen-
erated mkk7 /  BMMCs from 129/Ola mice, which have
Figure 3. Activation of mature T cells. (A) Immunocytometric analysis
of lymph node T cells in mkk7 /  and mkk7 /  chimeric mice. Cells
were isolated from 6-wk-old mice and stained with anti-CD4 and anti-
CD8. Percentages of positive cells within a quadrant are indicated. One
result representative of five independent experiments is shown. (B) Prolif-
eration of lymph node T cells. T cells were purified from lymph nodes of
mkk7 / rag1 /  and mkk7 / rag1 /  chimeric mice and activated (105 T
cells/well) with soluble anti-CD3  mAb (0.5  g/ml), soluble anti-CD3 
(0.1 g/ml) plus anti-CD28 (20 ng/ml) Abs in the presence or absence of
recombinant murine IL-2 (50 U/ml), Con A (2  g/ml), or PMA (10 ng/
ml) plus Ca2  ionophore (100 ng/ml) (PMA Iono). Mean proliferation
(  SD) was determined in triplicate at 48 h after a 12-h pulse with
[3H]thymidine. It should be noted that the surface marker phenotype and
activation status of T cells to be stimulated were similar in cells of both
genotypes; i.e., there was no bias in responder T cell populations. One re-
sult representative of five independent experiments is shown.763 Sasaki et al.
the same genetic background as the mkk7 /  E14 ES cells.
BMMCs of both genotypes showed similar expression lev-
els of c-Kit (SCF-R) and the IgE receptor (not shown),
two markers characteristic of mature BMMCs (37). Thus,
loss of MKK7 expression does not prevent the emergence
and differentiation of BMMCs. However, the proliferation
of mkk7 /  BMMCs in response to the mast cell growth
factor IL-3 (Fig. 5 A) or SCF (c-Kit-ligand; Fig. 5 B) was
strikingly increased compared with that of wild-type
BMMCs, paralleling the hyperproliferation observed in
mkk7-deficient thymocytes and B cells. Again, no signifi-
cant differences between mkk7 /  and mkk7 /  BMMCs were
observed in apoptosis induced by growth factor deprivation
or osmotic stress (NaCl) (not shown), or by anisomycin, heat
shock, or UV-irradiation (Fig. 5 C). Similar results were
obtained using in vitro differentiated Fc R c-Kit  mast
cell lines from mkk7 / , mkk7 / , and mkk7 /  ES cells
that were selected and differentiated under identical culture
conditions (not shown) (28). These data indicate that loss of
MKK7 results in the hyperproliferation of both lymphoid
and non-lymphoid hematopoietic cells in response to mul-
tiple growth factor or antigen receptor stimulation.
At the molecular level, immunoblot analyses of proteins
in BMMCs revealed that expression levels of p46 and p56
SAPK/JNK isoforms, p38 MAPK, ERK1/ERK2, PKB/
Akt, and actin were comparable in mkk7 /  and mkk7 / 
BMMCs (Fig. 6 A). However, expression of the cell cycle
inhibitory molecules, p16INK4a, which act principally on
cyclinD1 and CDK4-6, was completely abrogated in
mkk7 /  BMMCs, leading to a concomitant increase in
cyclinD1 expression (Fig. 6 A). Interestingly, whereas ex-
pression of c-Jun was comparable between mkk7 /  and
mkk7 /  BMMCs, expression of JunB, which has been
shown to upregulate p16INK4a expression (38), was mark-
Figure 4. B cells hyperproliferate in the absence of MKK7. (A) Immu-
nocytometric analysis of B cell populations in the bone marrow (top pan-
els) and spleen (bottom panels) of mkk7 /  and mkk7 /  chimeric mice.
Cells were isolated from 6-wk-old mice and double stained with anti-
B220 and anti-CD43, or anti-B220 and anti-sIgM. Percentages of posi-
tive cells within a quadrant are indicated. (B) Activation of splenic B cells.
Purified spleen cells (105/well) from mkk7 /  and mkk7 /  chimeric mice
were incubated for 36 h in medium alone (None) or medium containing
LPS (2  g/ml), anti-IgM (Fab )2 (5  g/ml), anti-CD40 (5  g/ml), or
anti-IgM (Fab )2 (5  g/ml) plus anti-CD40 (5  g/ml). Cells were labeled
with [3H]thymidine for the last 12 h of culture. The mean [3H]thymidine
uptake (  SD) of triplicate cultures is shown. Similar results were ob-
served when different seeding numbers were used and at earlier and later
time points of activation (not shown). One result representative of five
independent experiments is shown.
Figure 5. MKK7 regulates BMMC proliferation but not apoptosis. (A
and B) Proliferation of mkk7 /  and mkk7 /  BMMCs. mkk7 /  and
mkk7 /  BMMCs were incubated with increasing concentrations of (A)
IL-3 or (B) SCF (c-Kit-Ligand). [3H]Thymidine uptake was determined
24 h after cytokine addition. Similar results were obtained for five sepa-
rate cultures from five mice of each genotype. (C) Induction of apoptosis
in mkk7 /  and mkk7 /  BMMCs. Cells were stimulated for 14 or 42 h
with either anisomycin (Aniso; 10  M), UV-irradiation (500 mJ), or heat
shock (45 C for 30 min). Cell viability was determined in triplicate by
7-AAD and PI staining and normalized to the percentage of viable cells
in untreated cultures. One result of a triplicate culture (  SD) representa-
tive of five independent experiments is shown for each activation. Nor-
mal susceptibility to cell death of mkk7 /  BMMCs (P   0.1) was also
observed at various seeding numbers and in response to growth factor
deprivation and osmotic shock (not shown).764 Hematopoietic Cells Lacking MKK7 Hyperproliferate
edly decreased in mkk7 /  BMMCs. Expression of p27, an-
other cell cycle inhibitor, was not affected by the absence of
MKK7 (Fig. 6 A). However, it should be noted that loss
of MKK7 does not always result in downregulation of
p16INK4a expression, as p16INK4a expression appeared
normal in B220 IgM  B cells after in vitro differentiation of
mkk7 /  and mkk7 /  ES cells into B cells (Fig. 6 B, and
data not shown). Thus, mutation of mkk7 in BMMCs, but
not in B cells, results in loss of expression of JunB and the
cell cycle inhibitor p16INK4a and upregulation of cyclinD1.
MKK7 Is the Critical Mediator of SAPK/JNK Activation in
Mast Cells. The previous findings that SAPKs/JNKs
could be activated by both MKK4-dependent and MKK4-
independent signaling cascades (23–25), suggested that cells
can sense particular stresses and trigger distinct signaling
paths in response. To investigate whether similar MKK7-
dependent or -independent pathways might also control
SAPK/JNK activation, mkk7 /  and mkk7 /  BMMCs
were either treated with stress stimuli or activated via en-
gagement of membrane receptors, and the activation of
components of stress signaling pathways was assessed.
In wild-type BMMCs, SAPKs/JNKs are strongly acti-
vated in response to Fc  receptor stimulation (Fig. 6 C).
Moreover, SAPKs/JNKs are strongly activated after stimu-
lation with anisomycin, UV-irradiation, or NaCl (Fig. 6
D). However, IL-3, anisomycin, heat shock, UV-irradia-
tion, NaCl, cycloheximide, or TNF  used at various doses
and in a series of activation protocols failed to activate
SAPKs/JNKs in mkk7 /  BMMCs (Fig. 6, C and D, and
not shown). Fc R stimulation or anisomycin treatment led
to normal activation (phosphorylation) of p38 MAPK in
mkk7 /  BMMCs. Similarly, activation of ERK1/ERK2
and PKB/Akt induced by IgE plus antigen or IL-3 was
comparable in mkk7 /  and mkk7 /  BMMCs (not
shown). Thus, MKK7 is not required for the activation of
p38 MAPK, ERK1/ERK2, or PKB/Akt in BMMCs. In-
terestingly, whereas wild-type BMMCs expressed very low
levels of MKK4 protein regardless of stress stimulus, MKK4
was strongly upregulated in mkk7 /  BMMCs (Fig. 6 E).
Furthermore, the stimuli NaCl, anisomycin, UV-irradia-
tion, or heat shock, which did not activate SAPKs/JNKs in
the absence of MKK7 (Fig. 6 D), were able to induce
strong activation of MKK4, as detected by an Ab specific
for the phosphorylated form of MKK4 (Fig. 6 E). Thus, at
least in mast cells, MKK7 expression is essential for SAPK/
JNK activation, and upregulated levels of activated MKK4
alone are insufficient.
In Vitro Cooperation of Both MKK4 and MKK7 for Com-
plete SAPK/JNK Activation. The finding that MKK4
alone cannot activate SAPKS/JNKs in BMMCs may be ex-
plained in two ways. Either MKK4 is irrelevant for this
function in BMMCs or MKK4 and MKK7 cooperate in
vivo to achieve full SAPK/JNK activation. In an attempt to
establish a biochemical basis for cooperation, we designed an
in vitro kinase assay system in which purified recombinant
MKK4, MKK7, and SAPK  were mixed together followed
by assay of SAPK/JNK activity. Addition of either recombi-
nant wild-type MKK4 or wild-type MKK7 to SAPK /
JNK3 induced only moderate or low, respectively, levels of
SAPK /JNK3 kinase activity (Fig. 7). Even addition of a
constitutively active form of MKK7 (MKK7DE) induced
only moderate SAPK /JNK3 kinase activity. However, ad-
dition of both MKK4 and MKK7DE resulted in a dramatic
and synergistic induction of SAPK /JNK3 activation, strong
evidence of cooperativity between these two pathway inter-
mediates. Thus, MKK7 is an essential activator of SAPKs/
Figure 6. MKK7 is essential for SAPK/JNK activation in BMMCs. (A)
Western blot analysis of expression levels of total p54 and p46 SAPK/
JNK, p38 MAPK, ERK1, PKB/Akt, JunB, p16INK4a, p27, and
cyclinD1 in mkk7 /  (  / ) and mkk7 /  (    ) BMMCs. Actin is
shown as a loading control. Total cell lysate proteins (30  g/lane) were
separated by SDS-PAGE and incubated with Abs specific for the indi-
cated molecules. (B) Western blot analysis of expression levels of
p16INK4a and actin in mkk7 /  (  / ) and mkk7 /  (  / )
B220 IgM  B cells. B cells were differentiated in vitro from mkk7 / 
and mkk7 /  ES cells as described (reference 29). Total cell lysates of 106
cells were separated by SDS-PAGE and incubated with Abs specific for
the indicated molecules. (C and D) SAPK/JNK activity in mkk7 /  ( / )
and mkk7 /  ( / ) BMMCs. BMMCs were left untreated (None) or
activated with anti-DNP IgE (7  g/ml) plus DNP (50 ng/ml, 15 min),
IL-3 (30 ng/ml, 20 min), or anisomycin (Aniso; 10  g/ml, 20 min), heat
shock (heat; 45 C, 30 min), UV-irradiation (500 mJ, 15 min), NaCl (0.5 M,
10 min), cycloheximide (CHX; 50  g/ml, 20 min), TNF  (100 ng/ml,
20 min), or TNF  (100 ng/ml) plus CHX (50  g/ml) for 20 min. Total
SAPK/JNK was immunoprecipitated and assayed for in vitro kinase activ-
ity using GST-c-Jun as the substrate. In C, the levels of immunoprecipi-
tated p46 and p54 SAPK/JNK are shown as a loading control. One result
representative of four independent experiments is shown. (E) Expression
and phosphorylation (Thr223) of MKK4 in mkk7 /  ( / ) and mkk7 / 
( / ) BMMCs. BMMCs were stimulated with the indicated agents as in
B. Proteins were separated by SDS-PAGE and detected using an Ab reac-
tive to total MKK4 or an Ab specific for phospho-MKK4 (Thr223).
Thr223 phosphorylation is indicative of activated MKK4. Actin levels are
shown as a loading control.765 Sasaki et al.
JNKs in mast cells and its function is not redundant with that
of MKK4. Rather, at least in vitro, both MKK4 and MKK7
are necessary for complete SAPK/JNK activation.
Ectopic Expression of p16INK4a Reverts Hyperproliferation of
mkk7 /  BMMCs. Mutation of mkk7 in BMMCs results
in hyperproliferation, loss of expression of JunB and the
cell cycle inhibitor p16INK4a, and upregulation of cy-
clinD1 (Fig. 6 A). We therefore speculated that mutation
of mkk7 in BMMCs may results in hyperproliferation be-
cause reduced JunB expression and a loss of p16INK4a ex-
pression leads to upregulated cyclinD1 and accelerated cell
cycle progression. To address whether p16INKa has a role
in hyperproliferation of mkk7 /  BMMCs, we reexpressed
p16INK4a in mkk7-deficient BMMCs using a retroviral
expression vector (Fig. 8, inset). Importantly, reexpression
of p16INK4a suppressed hyperproliferation of mkk7 / 
BMMCs (Fig. 8). This result suggests that mkk7 deficiency
might cause downregulation of p16INK4a and subsequent
hyperproliferation of BMMCs.
Discussion
SAPKs/JNKs are activated in response to a variety of cel-
lular and environmental cues. To determine the role of the
SAPK/JNK activator MKK7 in hematopoietic cells, we
mutated both mkk7 alleles in ES cells using two selectable
markers and generated mkk7-deficient chimeric mice via
rag1 complementation. Surprisingly, mkk7 / rag1 /  chi-
meric mice exhibit markedly enlarged thymi and thy-
mocyte hyperproliferation. mkk7-deficient mature B cells
and mast cell lines also hyperproliferate in response to cy-
tokine and antigen receptor stimulation, but respond nor-
mally to death stimuli. In mast cells, the absence of MKK7
results in enhanced cell cycle progression, increased expres-
sion of cyclinD1, and significantly reduced expression of
the cyclin-dependent kinase inhibitor p16INK4a. In con-
trast, a deficiency of MKK7 does not affect the expression
of p27 nor the activation of ERK1/2 or p38 MAPK. Re-
expression of p16INK4a reduced the hyperproliferative
phenotype in mkk7 /  mast cells. Intriguingly, although
MKK4, the second direct SAPK/JNK activator, is strongly
upregulated in mkk7 /  mast cell lines and activated in re-
sponse to multiple stimuli, SAPK/JNK activation was still
completely abolished in response to these same stimuli in
the absence of MKK7. Thus, MKK7 is essential for SAPK/
JNK activation in mast cells and MKK7 acts as a negative
regulator of growth factor– and antigen receptor–induced
proliferation of different hematopoietic cell lineages.
The engagement of growth factor receptors or stimula-
tion by mitogens induces the activation of ERK1 and
ERK2 in many cell types and these kinases regulate the ac-
tivation of transcription factors governing cellular prolifera-
tion (39). SAPKs/JNKs are activated in response to a vari-
ety of environmental and cellular stresses such as metabolic
changes or DNA damage. These stresses can result in cell
cycle arrest to allow for repair. However, other than a pos-
itive regulatory role for MKK4 and JNK2 in antigen recep-
tor and CD28 costimulation-dependent proliferation of
mature T cells (9, 32), there is little in vivo data to suggest
that components of the stress signaling pathway can in fact
negatively regulate cell growth. Our results show that loss
of a stress signaling kinase, MKK7, results in hyperprolifer-
ation of thymocytes, mature B cells, mast cells (our results),
and possibly T cells (10). This hyperproliferation of mkk7 / 
hematopoietic cells appears to be due, not to impaired cell
death, but rather to enhanced cell cycle progression.
SAPKs/JNKs can associate with all three members of the
Jun-family of transcription factors, c-Jun, JunB, and JunD.
These molecules probably have specific and distinct func-
tions in cellular proliferation and depending on the stimu-
lus and cell type, can also mediate differentiation, cell
death, and/or growth arrest (40). In fibroblasts, expression
Figure 7. In vitro cooperation between MKK4 and MKK7 in
SAPK /JNK3 kinase activation. Purified GST-SAPK /JNK3 was incu-
bated with recombinant GST-MKK4 (wild-type MKK4), GST-MKK7
(wild-type MKK7), GST-MKK7DE (constitutively active MKK7), or
GST-MKK4 plus GST-MKK7DE for 30 min. SAPK /JNK3 activation
was measured by evaluating the amount of phosphorylated GST-c-Jun
produced. One result representative of five independent experiments is
shown for each lane.
Figure 8. Ectopic expression of p16INK4a results in reduction of
mkk7 /  BMMC hyperproliferation. Mkk7 deficient and wild-type
BMMCs were infected with empty virus (control) or p16INK4a ex-
pressing virus (p16) and selected for 1 wk with puromycin. After selec-
tion, cells were grown 3 more days without puromycin, and then, cell
growth (thymidine uptake) was examined in the presence of different
doses of IL-3. Expression of p16INK4a is shown (inset). One result repre-
sentative of three independent experiments is shown.766 Hematopoietic Cells Lacking MKK7 Hyperproliferate
of c-Jun has a positive effect on proliferation (41), whereas
Jun-D (42) and JunB (38) negatively regulate growth. It has
been recently shown that increased JunB expression in 3T3
fibroblasts induces high levels of p16INK4a but that other
cell cycle inhibitors are not affected (38). On the other
hand, c-Jun overexpression inhibits p16INK4a transcrip-
tion. Our data show that mkk7 /  BMMCs display re-
duced expression of JunB, completely lack expression of
p16INK4a, leading to dramatic upregulation of cyclinD1
expression. Thus, in the absence of MKK7, impaired c-Jun
and JunD phosphorylation and/or lower expression of and
deregulated JunB activity might explain the observed loss
of p16INKa expression and increase in cell growth. The
competing regulatory influences of JunB and c-Jun on
p16INK4a expression provide a molecular framework
within which SAPK/JNKs could conceivably control cell
growth (38). Consistent with this hypothesis, reexpression
of p16INK4a suppressed hyperproliferation of mkk7 / 
mast cells. However, we observed normal p16INK4a ex-
pression in in vitro differentiated B cells. Thus, it needs to
be determined whether, similar to BMMCs, hyperprolifer-
ation of mkk7 /  B cells and thymocytes might be also reg-
ulated by p16INK4a. Moreover, our data in mkk7 /  B
cells suggest that other molecular targets than p16INK4a
exist that control negative regulation of cell cycle progres-
sion downstream of MKK7. Identification of such targets
should be of interest to the understanding of development
and function of hematopoeitic lineages as well as the un-
derstanding of cellular transformation in leukemias.
It has been proposed that SAPK/JNK activation triggers
apoptosis in response to many types of stress, including UV
and  -irradiation, protein synthesis inhibitors, high osmo-
larity, toxins, ischemia/reperfusion injury in heart attacks,
heat shock, anti-cancer drugs, ceramide, peroxide, and in-
flammatory cytokines (3, 4). Several lines of evidence sup-
port this view. The overexpression of dominant negative
MKK4 can block the induction of cell death by heat shock,
irradiation, anti-cancer drugs, peroxide, ceramide, or cyto-
kine deprivation (43, 44). In addition, overexpression of
inactive c-Jun or dominant negative MEKK1 inhibits the
induction of apoptosis by irradiation, ceramide, or heat
shock in U937 and BAE cells (43), and protects PC12 cells
from apoptosis triggered by nerve growth factor (NGF)
withdrawal (45). These results suggested that the MKK →
SAPK/JNK  → c-Jun signaling cascade can transduce
proapoptotic signals.
However, recent studies of genetic “knockouts” of
SAPK/JNK isoforms and MKK4 have demonstrated that
MKK4 and SAPK/JNK activation are not essential for the
induction of cell death in response to all apoptotic stimuli.
For example, SAPK /JNK3 knockout mice are viable but
display a specific defect in kainate-induced apoptosis of hip-
pocampal neurons (11). Similarly, double mutation of jnk1/
jnk2 in primary murine fibroblasts protects them against
UV- and anisomycin-induced apoptosis (12). In contrast,
we (46) and others (25) have previously reported defective
liver formation and massive hepatocyte apoptosis in mouse
embryos lacking MKK4. In this case, MKK4 provides a
crucial and specific survival signal for hepatocytes during
embryonic morphogenesis. Additional genetic analyses of
mkk4-deficient ES cell clones and mouse embryonic fibro-
blasts have confirmed that both MKK4-dependent and
MKK4-independent pathways for SAPK/JNK activation
exist (23–25). MKK4 is the critical activator of SAPKs/
JNKs in response to anisomycin and heat shock, whereas
SAPK/JNK activation in response to osmolarity changes,
UV-irradiation,  -irradiation, or ceramide is independent
of MKK4, at least in these cells. Our experiments in mkk7 / 
BMMCs show that MKK7 is required for UV-, anisomy-
cin-, and NaCl-induced SAPK/JNK activation. However,
the kinetics and extent of UV-, anisomycin-, and NaCl-
induced apoptosis were comparable in mkk7 /  and mkk7 / 
BMMCs and thymocytes. Thus, although JNK1/2 might
be required to mediate UV- and anisomycin-triggered cell
death in fibroblasts (12), MKK7-controlled SAPK/JNK ac-
tivation does not have any apparent role in the apoptotic
response of mast cells and thymocytes to the same stimuli.
We conclude that, rather than being essential for apoptosis,
the MKK7-SAPK/JNK pathway modulates the death re-
sponse in a stimulus- and cell type–specific manner.
Signaling pathways for SAPK activation may also be
developmentally regulated during lymphopoiesis. PMA/
Ca2 -ionophore stimulation can induce SAPK/JNK activa-
tion in mature T cells from mkk4 / rag2 /  chimeric mice,
but not in immature thymocytes (32). Perhaps not coinci-
dentally, immature thymocytes express high levels of
MKK7 and low levels of MKK4, whereas mature T cells
express high levels of MKK4 and low levels of MKK7 (47,
48). Cell type–specific variation in expression of MKK7
and MKK4 in thymocytes versus mature T cells could ex-
plain the normal activation of mature lymph node T cells
but enhanced thymic cellularity and thymocyte hyperpro-
liferation observed in our mkk7 / rag1 /  chimeric mice.
The finding that different types of stress or different stages
of development trigger distinct signaling pathways for
SAPK/JNK activation has been explained by differential ac-
tivation of MKK4 and MKK7 via upstream kinases, and/or
differential scaffolding of the MKK4 and MKK7 signaling
pathways via adaptor molecules (49). It has further been
proposed that cells can sense different types of endogenous
or environmental stress signals and that MKK4- and MKK7-
mediated pathways of SAPK/JNK activation are controlled
by distinct “transducisomes”; that is, they are structurally
and/or biochemically separated (49). However, it has also
been reported that JNK1 (50) and JNK3 (51) are synergisti-
cally activated in vitro by the presence of both MKK4 and
MKK7, suggesting that complete activation of SAPK/JNK
enzymatic activity may sometimes require phosphorylation
by two different MKKs. This situation bears resemblance to
recent findings that two separate binding and phosphoryla-
tion events by MEK to its substrate ERK may be required
for complete ERK activation (52, 53).
The results of our in vitro kinase assays (Fig. 6 D) provide
further evidence that MKK4 and MKK7 must cooperate to
fully activate SAPKs/JNKs. Functional synergy between
MKK4 and MKK7 could explain why overexpression of767 Sasaki et al.
dominant inhibitory MKK4 or dominant-negative MKK7
inhibits activation of SAPK/JNK in response to multiple
stimuli. Whether the synergy between MKK4 and MKK7
in SAPK/JNK activation is a universal mechanism used by
other MKK isoforms needs to be tested. Importantly, our
results in mkk7 /  mast cells show that MKK7 expression is
required for SAPK/JNK activation in response to all stimuli
tested despite the fact that MKK4 expression is upregulated
and MKK4 is strongly phosphorylated. Impaired SAPK/
JNK activation in mkk7 /  mast cells despite increased
phosphorylation of MKK4 could be explained by func-
tional synergy between MKK4 and MKK7 in these cells in
vivo. Alternatively, MKK7 itself and/or an MKK7-associ-
ated molecule could provide a scaffold required for the in-
teraction between MKK4 and SAPK/JNKs. Such a mecha-
nism has been reported for Jun-B and c-Jun in which Jun-B
can recruit c-Jun to SAPKs/JNKs (54).
In conclusion, our data provide evidence that the stress
signaling kinase MKK7 is a negative regulator of growth
factor and antigen receptor–driven proliferation in hemato-
poietic cells. We have also demonstrated that MKK7 is es-
sential for SAPK/JNK activation in mast cells.
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